更新于：2024-12-06
Nicergoline
尼麦角林
更新于：2024-12-06
概要
基本信息
原研机构- |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H26BrN3O3 |
InChIKeyYSEXMKHXIOCEJA-FVFQAYNVSA-N |
CAS号27848-84-6 |
关联
33
项与 尼麦角林 相关的临床试验健康成年受试者空腹和餐后状态下单次口服尼麦角林片的随机、开放、单剂量、四周期、完全重复交叉设计的生物等效性试验
健康受试者餐后状态下单次口服尼麦角林片的生物等效性试验
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的生物等效性试验
100 项与 尼麦角林 相关的临床结果
登录后查看更多信息
100 项与 尼麦角林 相关的转化医学
登录后查看更多信息
100 项与 尼麦角林 相关的专利（医药）
登录后查看更多信息
412
项与 尼麦角林 相关的文献（医药）2024-12-01SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
Medications to Modify Aspiration Risk: Those That Add to Risk and Those That May Reduce Risk
Review
作者: Gonçalves-Pereira, João ; Froes, Filipe ; Mergulhão, Paulo
Abstract:
Aspiration pneumonia results from the abnormal entry of fluids into the respiratory tract. We present a review of drugs known to affect the risk of aspiration. Drugs that increase the risk of aspiration pneumonia can be broadly divided into those that affect protective reflexes (like cough and swallowing) due to direct or indirect mechanisms, and drugs that facilitate gastric dysbiosis or affect esophageal and intestinal motility. Chief among the first group are benzodiazepines and antipsychotics, while proton pump inhibitors are the most well-studied in the latter group. Pill esophagitis may also exacerbate swallowing dysfunction. On the other hand, some research has also focused on pharmaceutical modulation of the risk of aspiration pneumonia. Angiotensin-converting enzyme inhibitors have been demonstrated to be associated with a decrease in the hazard of aspiration pneumonia in high-risk patients of Chinese or Japanese origin. Drugs like amantadine, nicergoline, or folic acid have shown some promising results in stroke patients, although the available evidence is thus far not enough to allow for any meaningful conclusions. Importantly, antimicrobial prophylaxis has been proven to be ineffective. Focusing on modifiable risk factors for aspiration pneumonia is relevant since this may help to reduce the incidence of this often severe problem. Among these, several commonly used drug classes have been shown to increase the risk of aspiration pneumonia. These drugs should be withheld in the high-risk population whenever possible, alongside general measures, such as the semirecumbent position during sleep and feeding.
2023-08-01Apoptosis : an international journal on programmed cell death
Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues.
Review
作者: Reddy, Dibbanti HariKrishna ; Dhapola, Rishika ; Kumari, Sneha
Alzheimer's disease (AD) is characterized by the accumulation of hyperphosphorylated tau and amyloid-β (Aβ) protein resulting in synaptic loss and apoptosis. Aβ and tau deposition trigger apoptotic pathways that result in neuronal death. Apoptosis is considered to be responsible for manifestations associated with AD under pathological conditions. It regulates via extrinsic and intrinsic pathways. It activates various proteins including Bcl-2 family proteins like Bax, Bad, Bid, Bcl-XS, Bcl-XL and caspases comprising of initiator, effector and inflammatory caspases carried out through a cascade of events that finally lead to cell disintegration. The apoptotic elements interact with trophic factors, signaling molecules including Ras-ERK, JNK, GSK-3β, BDNF/TrkB/CREB and PI3K/AKT/mTOR. Ras-ERK signaling is involved in the progression of cell cycle and apoptosis. JNK pathway is also upregulated in AD which results in decreased expression of anti-apoptotic proteins. JAK-STAT triggers caspase-3 mediated apoptosis leading to neurodegeneration. The imbalance between autophagy and apoptosis is regulated by PI3K/Akt/mTOR pathway. GSK-3β is involved in the stimulation of pro-apoptotic factors resulting in dysregulation of apoptosis. Drugs like filgrastim, epigallocatechin gallate, curcumin, nicergoline and minocycline are under development which target these pathways and modulate the disease condition. This study sheds light on apoptotic pathways that are cardinal for neuronal survival and perform crucial role in the occurrence of AD along with the trends in therapeutics targeting apoptosis induced AD. To develop prospective treatments for AD, it is desirable to elucidate potential targets including restoration apoptotic balance, regulation of caspases, Bcl-2 and other crucial proteins involved in apoptosis mediated AD.
2023-02-07Eye & contact lens
Concomitant Bandage Contact Lens, Oral Nicergoline, and Topical Autologous Serum for Severe Neurotrophic Keratitis
Article
作者: Polania-Baron, Eduardo J ; Graue-Hernandez, Enrique O ; Ramirez-Miranda, Arturo ; Navas, Alejandro
Background::
To report the outcomes of using the combination of oral nicergoline, autologous serum, and contact lens to enhance corneal epithelization in neurotrophic keratitis and to discuss the clinical potential of this management.
Methods::
This was a prospective consecutive case series study of eight patients treated for neurotrophic keratitis at the “Conde de Valenciana” Institute of Ophthalmology. Oral nicergoline, autologous serum, and bandage contact lens were initiated at the same time, immediately after stage 3 diagnosis keratitis was confirmed clinically, and until corneal epithelialization was achieved or eminent corneal perforation was seen. In patients where diabetes was a cause, glycosylate hemoglobin was measured to asses metabolic control. Corneal esthesiometry and corrected distance visual acuity were assessed before and after treatment.
Results::
This study included eight eyes of eight patients (5 men [62.5%], average age 57±17.9 years). All patients completed at least 1 month of follow-up after nicergoline and contact lens suspension. Of the eight eyes, no one had positive culture growth and complete epithelial healing was achieved in all cases. Half of patients had diabetes and had a poor metabolic control. Corneal sensitivity improved in all eyes almost 2 centimeters in Cochet–Bonnet esthesiometry (P=0.01). In addition, final visual acuity gains were obtained (P=0.100).
Conclusions::
The combination of oral nicergoline, autologous serum, and bandage contact lens simultaneously could be an alternative in the management of stage 3 neurotrophic keratitis when conventional medical treatment has no improvement of corneal epithelization.
100 项与 尼麦角林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头晕 | 中国 | 2000-12-15 | |
| 智力障碍 | 中国 | 2000-12-15 | |
| 情绪障碍 | 中国 | 1999-09-17 | |
| 外周血管疾病 | 中国 | 1999-09-17 | |
| 动脉硬化 | 韩国 | 1978-12-16 | |
| 脑梗塞 | 韩国 | 1978-12-16 | |
| 痴呆 | 韩国 | 1978-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 阿尔茨海默症 | 临床3期 | 美国 | - | |
| 精神病性情感障碍 | 临床1期 | 中国 | 2020-04-30 | |
| 血管性痴呆 | 临床1期 | 中国 | 2020-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 8 | 艱窪壓製鹹蓋範構選獵(蓋糧構鑰糧獵遞廠顧積) = 壓築醖廠膚獵鏇鑰齋觸 鏇願蓋觸構鹽簾窪構鏇 (餘窪襯鏇壓鬱製艱廠鹽 ) | - | 2023-04-23 | |||
(Autologous Serum) | 艱窪壓製鹹蓋範構選獵(蓋糧構鑰糧獵遞廠顧積) = 築憲簾範網蓋網鬱繭觸 鏇願蓋觸構鹽簾窪構鏇 (餘窪襯鏇壓鬱製艱廠鹽 ) | ||||||
N/A | 9 | 願積鬱鏇構顧網襯範淵(艱積鑰艱淵網襯憲窪膚) = 繭壓築繭觸顧憲簾淵鹹 壓夢糧觸鑰獵選蓋築鹽 (範淵醖艱鏇衊鹹築鹹遞 ) | - | 2017-05-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用